These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32852603)

  • 1. Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer.
    Leary A; Genestie C; Blanc-Durand F; Gouy S; Dunant A; Maulard A; Drusch F; Cheaib B; Michels J; Bentivegna E; LeFormal A; Mesnage S; Morice P; Pautier P; Khairallah AS
    Cancer Immunol Immunother; 2021 Feb; 70(2):519-531. PubMed ID: 32852603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
    Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
    Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study.
    Cao G; Hua D; Li J; Zhang X; Zhang Z; Zhang B; Bei T; Cui L; Chen S; Wang S; Zhu L
    Front Immunol; 2023; 14():1022942. PubMed ID: 36993949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Neoadjuvant Chemotherapy on Ovarian Cancer Tumor Microenvironment: A Systematic Review of the Literature.
    Spagnol G; Ghisoni E; Morotti M; De Tommasi O; Marchetti M; Bigardi S; Tuninetti V; Tasca G; Noventa M; Saccardi C; Tozzi R; Dangaj Laniti D
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study).
    Tavira B; Iscar T; Manso L; Santaballa A; Gil-Martin M; García García Y; Romeo M; Iglesias M; de Juan Ferré A; Barretina-Ginesta MP; Manzano A; Gaba L; Rubio MJ; de Andrea CE; González-Martín A
    Clin Cancer Res; 2024 Jan; 30(1):176-186. PubMed ID: 37527007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.
    Khairallah AS; Genestie C; Auguste A; Leary A
    Int J Cancer; 2018 Jul; 143(1):8-15. PubMed ID: 29218796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
    Liang Y; Lü W; Zhang X; Lü B
    Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum-based neoadjuvant chemotherapy upregulates STING/IFN pathway expression and promotes TILs infiltration in NSCLC.
    Gao H; Zhang X; Ren M; Jiang A; Liu N; Wang J; Zheng X; Liang X; Ruan Z; Tian T; Fu X; Yao Y
    Front Oncol; 2024; 14():1346225. PubMed ID: 38425343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.
    Li J; Wang J; Chen R; Bai Y; Lu X
    Oncotarget; 2017 Feb; 8(9):15621-15631. PubMed ID: 28152503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
    D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
    Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Impact of Tumor-Infiltrating Immune Cells on Efficacy of Neoadjuvant Chemotherapy in Patients with Advanced or Metastatic Ovarian Cancer: A Retrospective Study.
    Rao Q; Huang M; Guan M; Liu C; Wang L; Lin Z; Chen Q
    Med Sci Monit; 2024 Jul; 30():e943170. PubMed ID: 39018268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
    Coleridge SL; Bryant A; Kehoe S; Morrison J
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
    van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
    Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer.
    Jlassi A; Manai M; Morjen M; Sahraoui G; Elasmi Allal M; ELBini-Dhouib I; Naija L; Charfi L; Rejaibi R; Ben Ahmed M; Marrakchi N; Srairi-Abid N; Mezlini A; Manai M; Mrad K; Doghri R
    PLoS One; 2023; 18(3):e0278849. PubMed ID: 36952478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of tumor infiltrating lymphocytes in high-grade serous ovarian carcinoma].
    Huang XM; Zhang Y; Xu L; Wang M; Wang W
    Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):610-614. PubMed ID: 31422591
    [No Abstract]   [Full Text] [Related]  

  • 16. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
    Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
    Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy.
    Yaniz-Galende E; Zeng Q; Bejar-Grau JF; Klein C; Blanc-Durand F; Le Formal A; Pujade-Lauraine E; Chardin L; Edmond E; Marty V; Ray-Coquard I; Joly F; Ferron G; Pautier P; Berton-Rigaud D; Lortholary A; Dohollou N; Desauw C; Fabbro M; Malaurie E; Bonichon-Lamaichhane N; Bello Roufai D; Gantzer J; Rouleau E; Genestie C; Leary A
    Clin Cancer Res; 2024 Jul; 30(13):2790-2800. PubMed ID: 38669064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathological analysis of tumor microenvironment in adrenocortical carcinoma: Possible effects of in situ disorganized glucocorticoid production on tumor immunity.
    Ishikawa Y; Yamazaki Y; Tezuka Y; Omata K; Ono Y; Tokodai K; Fujishima F; Kawanabe S; Katabami T; Ikeya A; Yamashita M; Oki Y; Nanjo H; Satoh F; Ito A; Unno M; Kamei T; Sasano H; Suzuki T
    J Steroid Biochem Mol Biol; 2024 Apr; 238():106462. PubMed ID: 38232786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric cancer immune microenvironment score predicts neoadjuvant chemotherapy efficacy and prognosis.
    Zhao S; Liu Y; Ding L; Zhang C; Ye J; Sun K; Song W; Cai S; He Y; Peng J; Xu J
    J Pathol Clin Res; 2024 May; 10(3):e12378. PubMed ID: 38778559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer.
    Ölmez F; Oğlak SC; Ölmez ÖF; Akbayır Ö; Yılmaz E; Akgöl S; Konal M; Seyhan NA; Kinter AK
    Turk J Obstet Gynecol; 2022 Sep; 19(3):246-256. PubMed ID: 36149309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.